Cancer Immunotherapies: What the Perioperative Physician Needs to Know

Purpose of Review For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. Recent Findings The perioperative period is a poignant moment in the journey o...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2022-04, Vol.24 (4), p.399-414
Main Authors: Ackerman, Robert S., Muncey, Aaron R., Aldawoodi, Nasrin N., Kotha, Rohini, Getting, Rosemarie E. Garcia
Format: Article
Language:English
Subjects:
Anesthesiology and Critical Care (JP Cata
Anesthesiology and Critical Care (JP Cata, Section Editor)
Cancer
Cancer immunotherapy
Heart diseases
Humans
Immune Checkpoint Inhibitors
Immunologic Factors
Immunotherapy
Immunotherapy - adverse effects
Medicine
Medicine & Public Health
Myocarditis
Neoplasms - pathology
Oncology
Oncolysis
Oncolytic Virotherapy
Patients
Pharmacodynamics
Pharmacokinetics
Physicians
Renal failure
Section Editor
Surgery
Toll-like receptors
Topical collection on Anesthesiology and Critical Care
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. Recent Findings The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immune-related adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. Summary Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-022-01202-6